Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs

被引:21
作者
Hammad, Tarek A. [1 ]
Graham, David J. [1 ]
Staffa, Judy A. [1 ]
Kornegay, Cynthia J. [1 ]
Dal Pan, Gerald J. [1 ]
机构
[1] US FDA, Off Surveillance & Epidemiol, Silver Spring, MD 20993 USA
关键词
nonsteroidal anti-inflammatory drugs; acute myocardial infarction; new user design;
D O I
10.1002/pds.1560
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 [公共卫生与预防医学]; 120402 [社会医学与卫生事业管理];
摘要
Purpose To examine the association between cyclooxygenase-2 (COX-2) selective and traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and incident acute myocardial infarction (AMI), and to address unanswered questions regarding the contour of risk over time. Methods A cohort of new NSAID users aged 40-84 years was followed for the occurrence of first AMI. Data were collected within the General Practice Research Database (GPRD) from I January 1997 to 31 December 2004. Results The study population included 1185 AMI events (889 probable and 296 possible) from a cohort of 283 136 patients. After adjustment for demographic and cardiovascular risk factors, the hazard ratio (HR) for AMI was significantly increased for both coxib (2.11, 95% confidence interval (CI) 1.04-4.26) and non-coxib (2.24, 95%CI 1.13-4.42) COX-2 selective NSAIDs when compared to remote exposure to NSAIDs, but was not increased for traditional NSAIDs. Stratifying exposure into the first month of use versus use beyond I month, the risk of AMI was increased during the first month of COX-2 selective NSAIDs use, but not later (3.43, 95%CI 1.66-7.07 and 1.88, 95%CI 0.82-4.31, respectively p-value for interaction = 0.6). Conclusions The results suggest that the use of coxib and non-coxib COX-2 selective NSAIDs was associated with an elevated risk of AMI within the first month of exposure. Recent past exposure to NSAID was not associated with a similar increase in risk. Copyright (c) 2008 John Wiley & Sons, Ltd.
引用
收藏
页码:315 / 321
页数:7
相关论文
共 35 条
[1]
Use of first- and second-generation cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction [J].
Andersohn, F ;
Suissa, S ;
Garbe, E .
CIRCULATION, 2006, 113 (16) :1950-1957
[2]
Bresalier RS, 2006, NEW ENGL J MED, V355, P221
[3]
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[4]
Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis [J].
Caldwell, B ;
Aldington, S ;
Weatherall, M ;
Shirtcliffe, P ;
Beasley, R .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2006, 99 (03) :132-140
[5]
Do some inhibitors of COX-2 increase the risk of thromboembolic events? Linking pharmacology with pharmacoepidemiology [J].
Clark, DWJ ;
Layton, D ;
Shakir, SAW .
DRUG SAFETY, 2004, 27 (07) :427-456
[6]
Current use of nonsteroidal antiinflammatory drugs and the risk of acute myocardial infarction [J].
Fischer, LM ;
Schlienger, RG ;
Matter, CM ;
Jick, H ;
Meier, CR .
PHARMACOTHERAPY, 2005, 25 (04) :503-510
[7]
Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population [J].
Garcia Rodriguez, Luis A. ;
Gonzalez-Perez, Antonio .
BMC MEDICINE, 2005, 3 (1)
[8]
Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [J].
Graham, DJ ;
Campen, D ;
Hui, R ;
Spence, M ;
Cheetham, C ;
Levy, G ;
Shoor, S ;
Graham, D .
LANCET, 2005, 365 (9458) :475-481
[9]
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities [J].
Grosser, T ;
Fries, S ;
FitzGerald, GA .
JOURNAL OF CLINICAL INVESTIGATION, 2006, 116 (01) :4-15
[10]
Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction [J].
Hernández-Díaz, S ;
Varas-Lorenzo, C ;
Rodríguez, LAG .
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2006, 98 (03) :266-274